A European patent granted for Medicortex

The European patent “A method for diagnosis of traumatic brain injury” (EP4483187) was granted by the EPO on 3 December 2025. The patent protects a method of detection and use of certain carbohydrate compositions as biomarkers of TBI. The markers can be detected in non-invasive samples of body fluid such as urine or saliva.

Medicortex has received another confirmation of its expertise in protecting innovative new technologies that the company has developed in-house by its experienced research team.

Dr. Adrian Harel, CEO of Medicortex says: "This is a great achievement - we are very pleased with the increase of our patent portfolio, company’s intellectual property covering methods of using certain biomarkers for detection of concussion and TBI. Issuance of this patent is another important step in the development of a new strategy to help identify and treat TBI."

Medicortex's patent portfolio encompasses biomarkers and methods of TBI detection as well as drug candidates developed by the company for halting the progression of TBI. The comprehensive patent coverage secures exclusivity to develop the products, and the company's strategy is to actively seek new patentable innovations from its biomarker and drug development programs.

Forward-looking statements

Certain statements in this communication are forward-looking statements. They are based on the views of the company’s management, as well as the understanding and assumptions of the company’s management based on the information available at present, and due to this, they may be forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors, which may result in that the company’s actual future results, operations, achievements and performance of the sector may differ significantly from the expectations conveyed in these statements. Forward-looking statements are not a guarantee of the company’s operational or financial performance in the future.